VERU — Veru Inc
NASDAQ · Healthcare · Biotechnology
$2.76
+$0.07 (+2.60%)
Veru Inc (VERU) is a biotechnology company listed on NASDAQ. It is led by Mitchell S. Steiner F.A.C.S., M.D., based in 2916 North Miami Avenue, Miami, FL, United States, 33127, with about 20 employees. Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Latest reported VERU revenue for 2025-06-30 was $0. Net income was -$7.3M. VERU currently screens at market cap $48.7M.
Use this VERU page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VERU quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VERU SEC filings page. Lician reads the product cache first so this HTML stays unique to Veru Inc even when a live quote feed is slow.
About Veru Inc
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
VERU Key Statistics
Market Cap
$48.71M
Volume
99,223
Previous Close
$2.64
Day Range
$2.50 – $2.64
P/B Ratio
1.44
EPS
$0.00
Revenue
$16.89M
Net Income
-$37.80M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+3.6%
Profit Margin
-223.9%
Employees
20
VERU Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $16.89M | $16.30M | $39.35M | $61.26M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$37.80M | -$93.15M | -$83.78M | $7.39M |
| EPS (Diluted) | $0.00 | -$1.10 | -$1.05 | $0.09 |
Total Assets
$60.42M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$24.92M
Operating Cash Flow
-$21.68M
Free Cash Flow
$0.00
Veru Inc Company Information
- Chairman, President & CEO
- Mitchell S. Steiner F.A.C.S., M.D.
- Headquarters
- 2916 North Miami Avenue, Miami, FL, United States, 33127
- Website
- verupharma.com
- Phone
- 305 509 6897
- IPO / Founded
- 1990-07-19
- Sector
- Healthcare
- Industry
- Biotechnology